Evie Ring (and EvieMED)

Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor, with cycle tracking and women's-health metrics as its editorial differentiator. A load-bearing entity split applies: there are two rings, the consumer Evie Ring, which tracks the menstrual cycle, sleep, energy, heart rate, blood oxygen, and mood as a general-wellness device that is not FDA-cleared, and the separate business-to-business EvieMED Ring, which received an FDA 510(k) clearance for its pulse oximeter and heart rate on December 2, 2024 for clinical trials, remote patient monitoring, and payor and pharma use, with a pivotal study showing accuracy across darker skin tones, so the clearance must not be attributed to the consumer Evie Ring. A significant financial cap-flag is the real risk here: Movano is distressed, with its SEC filings showing going-concern substantial doubt, an accumulated deficit of $160.5 million as of September 30, 2025, cash not sufficient to fund operations beyond the first quarter of 2026 without further capital or a merger, a strategic review and possible sale underway, a one-for-ten reverse stock split in October 2025 to regain NASDAQ compliance, and a $1.5 million bridge loan at an effective rate around 111.6 percent secured by the company's intellectual property that transfers to the lender if a merger fails to close, so the registry records it at commercial maturity but at risk with an active lifecycle and a re-verification flag given the volatile status. A source-drift note: a secondary article cites a stale 2024 cash figure that the SEC filings supersede with the going-concern position, and the company's market-size framing is total-addressable-market language rather than verified revenue.

Evie Ring (and EvieMED)'s price is not publicly disclosed. DEPLOY has no verified price on record for Evie Ring (and EvieMED) from Movano Health. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.

Yes. Evie Ring (and EvieMED) is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Evie Ring (and EvieMED) is made by Movano Health, based in Pleasanton, California, USA, founded in 2018.

1 verified deployment of Evie Ring (and EvieMED) is on the DEPLOY registry, including at United States.

Evie Ring (and EvieMED) is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.

On the DEPLOY registry, comparable biometric robots to Evie Ring (and EvieMED) include Blackrock Neuroport Array, BrainQ Non-Invasive BCI, Neko Body Scan, RNS System.

Evie Ring (and EvieMED) and Blackrock Neuroport Array (Blackrock Neurotech · 5 deployments) are both biometric robots on the DEPLOY registry. Evie Ring (and EvieMED) has 1 verified deployment on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Evie Ring (and EvieMED) ranks in roughly the top 97% of biometric models tracked by the registry.

Evie Ring (and EvieMED) is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Evie Ring (and EvieMED) is currently paused on the DEPLOY registry: operations are suspended but expected to resume.

Evie Ring (and EvieMED) has 1 active incident on record in the DEPLOY registry. 1 incident on record (1 minor). Most recent: Jun 2026. Retracted incidents are excluded from this count.